The reduction in price target by RBC Capital is a minor adjustment, suggesting a slight change in valuation but not a change in overall company outlook. The 'Sector Perform' rating indicates that the analyst's view on Gilead Sciences remains neutral, and thus the short-term impact on the stock price is likely to be limited.